5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell Lymphoma.

Journal: International journal of radiation oncology, biology, physics
Published Date: Apr 3, 2025

Abstract

PURPOSE: Bridging radiation therapy (BRT) is effective for local control in patients with relapsed or refractory large B cell lymphoma who are undergoing chimeric antigen receptor (CAR) T cell therapy. We hypothesized that adaptive BRT (ABRT), which can be used to personalize the radiation dose, fractionation, and volume based on real-time lymphoma target volume, is feasible, safe, and effective for local control.

Authors

  • Hazim S Ababneh
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Andrea K Ng
    Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Joshua Wan
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Tyler Walburn
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Lin Zhu
    Institute of Environmental Technology, College of Environmental and Resource Sciences; Zhejiang University, Hangzhou 310058, China.
  • Mislav Bobic
    Varian Medical Systems Imaging Laboratory, Taefernstrasse 7, 5405 Daettwil AG, Switzerland.
  • Patrick Connor Johnson
    Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Jeremy Bredtfeld
    Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Jonathan Leeman
    Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Jacob Soumerai
    Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Jeremy S Abramson
    Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Jeffrey Barnes
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
  • Ronald Takvorian
    Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Matthew J Frigault
    Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Jennifer Pursley
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
  • Chirayu G Patel
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: cpatel@mgh.harvard.edu.

Keywords

External Resources

Popular Topics
Recent Journals